Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,891 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply: RE: Reyes A, Revil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087.
Reyes A, Révil C, Niggli M, Chebon S, Schlagmüller S, Flacke JP, Zortel M, Paz-Priel I, Asikanius E, Hampton R, Mahajan A, Schmidt E, Edwards SC. Reyes A, et al. Curr Med Res Opin. 2020 Jul;36(7):1129-1130. doi: 10.1080/03007995.2020.1744550. Epub 2020 Apr 7. Curr Med Res Opin. 2020. PMID: 32180474 Updated. No abstract available.
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
Reyes A, Révil C, Niggli M, Chebon S, Schlagmüller S, Flacke JP, Zortel M, Paz-Priel I, Asikanius E, Hampton R, Mahajan A, Schmidt E, Edwards SC. Reyes A, et al. Curr Med Res Opin. 2019 Dec;35(12):2079-2087. doi: 10.1080/03007995.2019.1649378. Epub 2019 Aug 13. Curr Med Res Opin. 2019. PMID: 31355677
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.
Paracha N, Reyes A, Diéras V, Krop I, Pivot X, Urruticoechea A. Paracha N, et al. Among authors: reyes a. Breast Cancer Res Treat. 2020 Apr;180(3):597-609. doi: 10.1007/s10549-020-05577-7. Epub 2020 Feb 25. Breast Cancer Res Treat. 2020. PMID: 32100144 Free PMC article.
Racial and ethnic diversity in global neuroscience clinical trials.
Rutten-Jacobs L, McIver T, Reyes A, Pereira M, Rosenthal R, Parusel CT, Wagner KR, Doody R. Rutten-Jacobs L, et al. Among authors: reyes a. Contemp Clin Trials Commun. 2024 Jan 4;37:101255. doi: 10.1016/j.conctc.2024.101255. eCollection 2024 Feb. Contemp Clin Trials Commun. 2024. PMID: 38292216 Free PMC article.
Benchmarking tools for transcription factor prioritization.
Santana LS, Reyes A, Hoersch S, Ferrero E, Kolter C, Gaulis S, Steinhauser S. Santana LS, et al. Among authors: reyes a. Comput Struct Biotechnol J. 2024 May 11;23:2190-2199. doi: 10.1016/j.csbj.2024.05.016. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 38817966 Free PMC article.
1,891 results